CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab by Skougaard, Kristin et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal
cancer treated with irinotecan and cetuximab
Skougaard, Kristin; Johannesen, Helle Hjorth; Nielsen, Dorte; Schou, Jakob Vasehus;
Jensen, Benny Vittrup; Høgdall, Estrid V S; Hendel, Helle Westergren
Published in:
Cancer Medicine
DOI:
10.1002/cam4.271
Publication date:
2014
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Skougaard, K., Johannesen, H. H., Nielsen, D., Schou, J. V., Jensen, B. V., Høgdall, E. V. S., & Hendel, H. W.
(2014). CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with
irinotecan and cetuximab. Cancer Medicine, 3(5), 1294-1301. https://doi.org/10.1002/cam4.271
Download date: 03. Feb. 2020
ORIGINAL RESEARCH
CT versus FDG-PET/CT response evaluation in patients with
metastatic colorectal cancer treated with irinotecan and
cetuximab
Kristin Skougaard1, Helle Hjorth Johannesen2, Dorte Nielsen1, Jakob Vasehus Schou1, Benny Vittrup
Jensen1, Estrid V. S. Høgdall3 & Helle Westergren Hendel4
1Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark
2Department of Radiology, Copenhagen University Hospital Rigshospitalet, Herlev, Denmark
3Department of Pathology, Copenhagen University Hospital Herlev, Herlev, Denmark
4Department of Nuclear Medicine, Copenhagen University Hospital Herlev, Herlev, Denmark
Keywords
Colorectal cancer, KRAS, PERCIST, PET/CT,
RECIST, response evaluation, survival
Correspondence
Kristin Skougaard, Department of Oncology,
Copenhagen University Hospital Herlev,
Herlev Ringvej 75, 2730 Herlev, Denmark.
Tel: +4561776860; Fax: +4538683507;
E-mail: kristinskougaard@dadlnet.dk
Funding Information
No funding information provided.
Received: 7 August 2013; Revised: 21 April
2014; Accepted: 30 April 2014
Cancer Medicine 2014; 3(5): 1294–1301
doi: 10.1002/cam4.271
Abstract
We compared morphologic computed tomography (CT)-based to metabolic flu-
oro-deoxy-glucose (FDG) positron emission tomography (PET)/CT-based
response evaluation in patients with metastatic colorectal cancer and correlated
the findings with survival and KRAS status. From 2006 to 2009, patients were
included in a phase II trial and treated with cetuximab and irinotecan every sec-
ond week. They underwent FDG-PET/CT examination at baseline and after every
fourth treatment cycle. Response evaluation was performed prospectively accord-
ing to Response Evaluation Criteria in Solid Tumors (RECIST 1.0) and retrospec-
tively according to Positron Emission Tomography Response Criteria in Solid
Tumors (PERCIST). Best overall responses were registered. Sixty-one patients
were eligible for response evaluation. Partial response (PR) rate was 18%, stable
disease (SD) rate 64%, and progressive disease (PD) rate 18%. Partial metabolic
response (PMR) rate was 56%, stable metabolic disease rate 33%, and progressive
metabolic disease (PMD) rate 11%. Response agreement was poor, j-coefficient
0.19. Hazard ratio for overall survival for responders (PR/PMR) versus nonre-
sponders (PD/PMD) was higher for CT- than for FDG-PET/CT evaluation.
Within patients with KRAS mutations, none had PR but 44% had PMR. In con-
clusion, morphologic and metabolic response agreement was poor primarily
because a large part of the patients shifted from SD with CT evaluation to PMR
when evaluated with FDG-PET/CT. Furthermore, a larger fraction of the patients
with KRAS mutations had a metabolic treatment response.
Introduction
Computed tomography (CT) is still the most frequently
used imaging modality for response assessment of patients
with metastatic colorectal cancer (mCRC) [1, 2] and
Response Evaluation Criteria in Solid Tumors (RECIST
1.0) [3] are the most frequently applied criteria. Also,
assessing treatment response with fluorine-18 fluoro-
deoxy-glucose-positron emission tomography/CT (FDG-
PET/CT) has shown to be resourceful for both response
prediction and evaluation of cancer patients [4–8] and to
correlate well with survival [9, 10] in spite of greatly
different outcomes, including higher response rates (RRs),
than seen with CT [11–13]. This tendency is seen with
chemotherapy and furthermore with targeted therapies [8,
11, 14] suggesting that in this setting, visualization of
metabolism could be a suitable mean for response assess-
ment [14–16]. In clinical phase II trials, patients with
complete response (CR), partial response (PR), and stable
disease (SD) will continue treatment until progression is
verified by CT. Yet, it is the response rate (RR = fraction
of patients with CR and PR) that determines whether a
tested drug or regimen will be further investigated in a
phase III trial or implemented as standard treatment. Low
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RRs from CT-based trials could lead to efficacy underesti-
mation of potentially active targeted treatments and
maybe in withdrawal rather than further testing [14, 15].
Choosing a response evaluation modality and method
that, as precisely as possible, reflects the investigated
drug’s mode of action is, therefore, important in order to
present accurate and applicable RRs.
Approximately 35% of patients with CRC harbor a
codon 12/13 mutation in the cancer cell proto-oncogene
KRAS. Studies, using CT-based response evaluation, have
shown that KRAS mutation is a negative predictive mar-
ker of morphologic response to the monoclonal antibody
cetuximab [17, 18]. The effect of cetuximab on tumor
metabolism, visualized by FDG-PET/CT, has not been
investigated in patients with mCRC harboring KRAS
mutations. Applying both morphologic and metabolic
response visualization, as done in the present investiga-
tion, will elucidate the differences between the two meth-
ods and clarify how FDG-PET/CT response evaluation
and KRAS mutation status is correlated.
In this study, we compared CT response evaluation
with RECIST 1.0 to FDG-PET/CT response evaluation
with Positron Emission Tomography Response Criteria in
Solid Tumors (PERCIST) [19] and correlated the findings
to overall survival (OS) and KRAS status.
Patients and Methods
Patients
From 2006 to 2009, patients with mCRC were, regardless of
KRAS mutation status, prospectively included in a phase II
trial and treated every second week with a combination of
the epidermal growth factor receptor (EGFR) specific
monoclonal antibody cetuximab (Erbitux; Merck, Darm-
stadt, Germany; 500 mg/m²) and the chemotherapeutic
drug irinotecan (Irinotecan; Fresenius Kabi Oncology, Bad
Homburg, Germany; 180 mg/m²) as 3rd line palliative
treatment. The protocol was approved by the Danish
Regional Research Ethics Committee, The Danish Medi-
cines Agency (EudraCT nr. 2006-001961-40), and The Data
Protection Agency. Oral and written informed consent was
obtained from all patients before inclusion.
The patients were scanned between 1 and 14 days prior
to the first treatment and after every fourth treatment
cycle until progression was established according to
RECIST. Prednisolone was only administered to the patients
on the day of treatment and the two following days.
FDG-PET/CT examinations
The patients were examined from base of scull to mid-
thigh on one of two different scanners: Philips Gemini
Dual Slice PET/CT (Gemini DS) or Philips Gemini Tru-
FlightTM (TF) 16-slice PET/CT (Gemini TF) (Philips Med-
ical Systems, Cleveland, OH). Philips Extended Brilliance
Workspace Nuclear Medicine version 2.0, Tumor Track-
ing was used to draw regions of interest (ROIs). The
applied tracer was [18] F-FDG. It was injected intrave-
nously (i.v.) with an aimed dose of 370  10% MBq.
The patients fasted ≥5 h before scan start. Blood glucose
was measured immediately before tracer injection and
patients with levels ≥8 mmol/L were excluded. Uptake
time from tracer injection to onset of emission scan was
aimed at 60  10% min. The multidetector spiral CT
scans were standard diagnostic contrast-enhanced examin-
ations covering the thorax, abdomen, and pelvis. Iodin-
ated contrast agent (Omnipaque 350; GE Healthcare,
Oslo, Norway) was given orally: 20 mL in 500 mL bottled
water (4% solution) half an hour before scan start, and
i.v.: 100 mL with an injection flow of 5 mL/sec immedi-
ately before scan start.
It was intended to examine each patient on the same
scanner throughout their treatment course. Patients who
were examined on the two scanners in a manner preclud-
ing response evaluation were excluded, whereas patients
with one or few examinations performed on the scanner
different from their baseline-scanner were included if
elimination of the irregular examinations was possible
without affecting response evaluation.
The PET and the CT scan were described separately in
the Department of Nuclear Medicine and in the Depart-
ment of Radiology, respectively. Thereafter, a joint con-
clusion, containing both convergent and divergent
findings, was performed in collaboration between the
nuclear physiologist and the radiologist. Neither were
blinded to previous scans and both had in principal
access to their opposite scans. Continuation or termina-
tion of treatment was based on the prospective CT
response evaluation only. PET evaluation was performed
retrospectively.
Response evaluation with RECIST
Target lesions, up to five per organ and 10 in total, were
chosen on the baseline CT, measured in the longest diam-
eter and the diameters were summed. On each subsequent
examination, the target lesions were measured and
summed. Nontarget lesions were registered at baseline
and described on each subsequent examination. Response
was calculated as Δ∑longest diameter between baseline
and actual follow-up divided by baseline ∑longest diame-
ter 9 100%. If ∑longest diameter increased, response was
calculated as ∑longest diameter between lowest registered
and actual ∑longest diameter divided by lowest registered
∑longest diameter 9 100%.
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Responses were, according to RECIST [3], categorized
in CR, PR, SD, and progressive disease (PD). The best
overall morphologic response (BOR) achieved by each
patient during treatment was registered. RR, clinical bene-
fit rate (CBR = fraction of patients with CR, PR and
SD ≥ 6 months) and disease control rate (DCR = fraction
of patients with CR, PR, and SD) were calculated.
Response evaluation with PERCIST
FDG-uptake was normalized to lean body mass (lbm) and
termed standard uptake value-lbm (SUL). Background
and lesion ROIs were drawn according to the guidelines
[19]. In the hottest (= highest FDG-uptake) part of the
hottest lesion, a 1.2-cm-diameter spherical ROI (~1 cm3)
was drawn. The ROI was placed where it resulted in the
highest possible SULmean value = SULpeak. The hottest
lesion during follow-up could be a lesion different from
the previously measured; presupposing it had been present
since baseline. If baseline SULpeak in the single hottest
lesion did not exceed the defined background value, the
patient was not eligible for response evaluation. Response
was calculated as ΔSULpeak between baseline and actual
follow-up divided by baseline SULpeak 9 100%. If SUL-
peak increased, response was calculated as ΔSULpeak
between lowest registered SULpeak and actual SULpeak
divided by lowest registered SULpeak 9 100%.
Responses were categorized according to PERCIST [19] in
complete metabolic response (CMR), partial metabolic
response (PMR), stable metabolic disease (SMD), and pro-
gressive metabolic disease (PMD). Best overall metabolic
response (BOMR) achieved by each patient during treatment
was registered and metabolic response rate (MRR = fraction
of patients with CMR and PMR) was calculated.
KRAS analysis
Formalin-fixed paraffin-embedded tumor tissue, collected
at the time of diagnosis, was used to evaluate and confirm
the presence of tumor tissue. Verification of tumor cells
was done by hematoxylin and eosin staining. DNA
extracted from three sections was subjected to Thera-
screen KRAS real-time PCR assays (DxS Ltd, Manches-
ter, U.K.), which identified seven mutations in codon 12
and codon 13 using an ABI7500 real-time PCR platform.
The patients were classified as harboring KRAS mutations
if one of the seven mutations were present or as KRAS
wild-type if no mutations were present [20, 21].
Statistical analysis
The kappa statistic was used for agreement analysis. The
Kaplan–Meier method was used for OS analysis with the
log-rank test for P-value calculation and Cox-regression
analyses for hazard ratio (HR) and confidence interval
(CI) calculations. OS was defined as time from trial regis-
tration of a patient until death of any course.
Results
Patients
Among 150 included patients, 131 were examined with
FDG-PET/CT during their treatment course. Of these, 13
patients were never scanned and never treated and 37
were excluded due to their own wish, anaphylactic reac-
tions to the first treatment or clinical progression before
first follow-up. One patient with bg ≥ 8, one with no
measurable disease on PET, and four with unavailable
PET images were excluded. Furthermore, two patients
without target lesions according to PERCIST and 12 that
were examined on the two different scanners in a manner
preventing response evaluation were excluded. Ultimately,
61 patients were eligible for response evaluation with CT
and FDG-PET/CT. Characteristics are given in Table 1.
Of the total 230 examinations, 27 were not performed
on the scanner the individual patient was examined in at
baseline and were, therefore, excluded; leading to 203 eli-
gible FDG-PET/CT examinations. Fifty-six patients were
evaluated with examinations from the Philips Gemini DS
scanner and five with examinations from the Philips
Gemini TF scanner. The mean FDG-dose was 371  25
(standard deviation [SD]) MBq and the mean uptake
time was 67  10 (SD) min.
Response evaluation
None of the patients had CR or CMR. According to RE-
CIST, 11 patients (18%) had PR, 39 (64%) had SD, and
11 (18%) had PD as their BOR (Fig. 1 and Table 3). The
RR was 18%.
According to PERCIST, 34 patients (56%) had PMR,
20 (33%) had SMD, and seven (11%) had PMD as their
BOMR (Fig. 1 and Table 3). The MRR was 56%. RECIST
1.0 and PERCIST agreed on BOR/BOMR in 28 out of 61
patients (46%). The corresponding j-coefficient was 0.19
and strengths of agreement poor (Table 2). In 35 patients
(57%) PD and PMD were coincident. In 11 patients
(18%) PMD had occurred earlier than PD was stated and
in 15 patients (25%) PMD had not yet occurred at the
time of PD.
Correlation with overall survival
On 1st February 2012, two patients were still alive. The
correlation between RECIST and PERCIST evaluation and
1296 ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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OS as well as group-wise median OS and corresponding
95% CI are shown in Figures 2, 3. Survival of the patients
in the PR group was not significantly longer than for the
patients in the SD group although a trend in this direc-
tion was observed (P = 0.082, HR = 1.9, CI = 0.9–3.8),
but was significantly longer than for the patients in the
PD group (P = 0.001, HR = 5.4, CI = 2.1–13.9). Due to
the low number of patients with PMD (seven), this group
was added to the SMD group for the Kaplan–Meier plot
of OS. OS of patients with PMR was significantly longer
than for patients with SMD (P = 0.0005, HR = 3.6,
CI = 2.0–6.7) and for patients in the combined
0%
10%
20%
30%
40%
50%
60%
70%
PR PMR SD SMD PD PMD
BOR/BOMR
Mutated
Wild-type
Unknown
18%
56%
64%
33%
18%
11%
Figure 1. BOR/BOMR according to RECIST and PERCIST. P(M)R,
partial (metabolic) response; S(M)D, stable (metabolic) disease; P(M)D,
progressive (metabolic) disease; BO(M)R, best overall (metabolic)
response.
Table 2. Agreement on BOR/BOMR between CT- and FDG-PET/CT-
based response evaluations.
Response RECIST 1.0
Response
PERCIST CR PR SD PD
Total
PERCIST
CMR 0 0 0 0 0
PMR 0 10 20 4 34
SMD 0 1 15 4 20
PMD 0 0 4 3 7
Total RECIST 0 11 39 11 61
CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease; CMR, complete metabolic response; PMR, partial
metabolic response; SMD, stable metabolic disease; PMD, progressive
metabolic disease.
Group-wise comparison: 
PR/SD: P = 0.082
PR/PD: P = 0.001
SD/PD: P = 0.004
Median survival (months):
PR: 21.4 (CI: 11.8–31.0)
SD: 12.2 (CI: 8.7–15.7)
PD: 7.9 (CI: 3.8–12.0) 
HR and CI:
PR: 1 (ref)
SD: 1.9 (0.9–3.8)
PD: 5.4 (2.1–13.9)
RECIST 1.0
Figure 2. Correlation between survival and response category
according to RECIST. PR, partial response; SD, stable disease; PD,
progressive disease; HR, hazard ratio; CI, confidence interval.
Table 1. Characteristics of the 61 evaluated patients.
Characteristics Value
Age (years)
Median 62
Range 36–82
Sex (number of patients)
Female 24
Male 37
Weight (kg)
Median 77
Range 49–118
Number of metastatic sites
Median 2
Range 1–4
KRAS status
Wild-type 42 (69%)
Mutations 18 (30%)
Unknown 1 (~1%)
Number of treatments per patient
Median 8
Range 4–28
Number of examinations
Total 203
Median 3
Range 2–7
Scanner (number of patients)
Philips Gemini dual slice 56
Philips TF 16 slice 5
Treatment received after progression to the protocol-treatment
(irinotecan + cetuximab)
No treatment 30
Cetuximab + irinotecan
+ sunitinib
23
Cetuximab + irinotecan
+ bevazicumab
3
Other 5
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SMD + PMD group (P = 0.0008, HR = 2.5, CI = 1.4–
4.2) but not for patients with PMD (P = 0.505, HR = 1.3,
CI = 0.5–3.1).
Correlation with KRAS
Forty-two (69%) patients had KRAS wild-type and 18
(30%) harbored KRAS mutations. One patient’s mutation
status was not possible to define. None of the patients
with PR, 34% of the patients with SD, and 45% of the
patients with PD harbored KRAS mutations (Fig. 1).
Twenty-four% of the patients with PMR, 42% of the
patients with SMD, and 29% of the patients with PMD
had KRAS mutations (Fig. 1 and Table 3).
Discussion
We compared CT-based with FDG-PET/CT-based
response evaluation of patients with mCRC treated with
cetuximab and irinotecan and found morphologic and
metabolic response assessment to be incongruent with
poor agreement on BOR/BOMR. The PMR rate was
threefold higher than the PR rate, and the SMD and
PMD rates lower than the SD and PD rates. HR for OS
for responders (PR/PMR) versus nonresponders (PD/
PMD) was higher for CT- than for FDG-PET/CT evalua-
tion and in general, correlation with survival varied with
evaluation method. In contrast to no patients with PR,
24% of the patients with PMR harbored KRAS mutations
equal to 44% of the total number of patients with KRAS
mutations.
The RR of irinotecan and cetuximab in 3rd line pallia-
tive therapy of mCRC patients has by other study groups
been found to be 19–23%, similar to the 18% we found
in our study [22–24]. In patients with mCRC receiving
chemotherapy, primarily in 1st line, Monteil et al. [11]
found an MRR of 84% which is somewhat higher than
the MRR of 54% in our patient group, presumably due
to difference in line of treatment. The low agreement on
BOR/BOMR in our study is in line with Monteil et al.
[11], who likewise found a considerable fraction of the
patients shifting from the SD group to the PMR group
when response evaluation shifted from CT- to FGD-PET/
CT-based. Additionally, the significant difference in sur-
vival between the PMR group and the SMD + PMD
group found in our study is consistent with the findings
of de Geus-Oei et al. [9, 10] who demonstrated a signifi-
cantly longer median survival of patients with marked
reductions in SUV compared to patients without in
mCRC and nonsmall cell lung cancer.
An advantage of this study is that all CT examinations
were performed as FDG-PET/CT examinations. This
allowed comparison of BOR from CT evaluation to
BOMR from FDG-PET/CT evaluation. Awareness of
Group-wise comparison: 
PMR/SMD: P < 0.0005
PMR/PMD: P = 0.505
SMD/PMD: P = 0.074 
PMR/SMD+PMD: P = 0.0008 
Median survival (months):
PMR: 14.5 (CI: 10.5– 18.5)
SMD: 6.9 (CI: 3.8–10.0) (curve not shown)
PMD: 12.2 (CI: 9.6–14.8) (curve not shown)
SMD+PMD: 7.9 (CI: 5.7–10.1)
HR and CI
PMR: 1 (ref) (shown curve)
SMD: 3.6 (2.0–6.7)
PMD: 1.3 (0.5–3.1)
SMD/PMD: 2.5(1.4–4.2)
PERCIST
Figure 3. Correlation between survival and response category
according to PERCIST. PMR, partial metabolic response; SMD, stable
metabolic disease; PMD, progressive metabolic disease; HR, hazard
ratio; CI, confidence interval.
Table 3. Response categories distribution of all patients and according to KRAS status.
RECIST PERCIST
Patient group
Total no.
of patients
PR
No. (%)
SD
No. (%)
PD
No. (%)
PMR
No. (%)
SMD
No. (%)
PMD
No. (%)
All 61 11 (18) 39 (64) 11 (18) 34 (56) 20 (33) 7 (11)
KRAS wt 42 11 (26) 25 (60) 6 (14) 26 (62) 11 (26) 5 (12)
KRAS mut 18 0 (0) 13 (72) 5 (28) 8 (44) 8 (44) 2 (11)
One patient’s mutation status was not possible to define.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CMR, complete metabolic response; PMR, partial meta-
bolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease; wt, wild-type; mut, mutations.
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imaging modality-dependent differences in response out-
come could facilitate choices of optimal imaging modali-
ties for response assessment in clinical trials and in
standard clinical care. Our study had several limitations.
Treatment was terminated at the time point when PD
was established on CT regardless of progression status
according to FDG-PET/CT. This hindered comparison of
progression-free survival (PFS) from the two evaluation
methods and PFS would in this phase II trial have been a
more relevant secondary endpoint than OS. Also, to rep-
resent the whole colorectal cancer population, the number
of included patients in our trial is relatively low. How-
ever, with 61 patients, it is one of the largest studies in
the field. Furthermore, in order to verify the differences
depending on the addition of cetuximab to irinotecan, a
control group receiving only chemotherapy would have
greatly strengthened the study.
The main response outcome difference was the major
shift of patients from SD to PMR, showing that tumor
size can remain relatively unchanged while tumor metabo-
lism simultaneously can be markedly reduced. Cetuximab
and targeted therapies in general tend to be cytostatic
rather than cytotoxic with a somewhat varying effect on
tumor size correlated to the target of the therapy [16, 25].
They halt tumor growth by inhibiting proliferation, angio-
genesis, and metastatic spread and by promoting apopto-
sis [25–27]. This reduces tumor metabolism but do not
necessarily cause a measurable reduction in tumor size
[14, 15]. Due to this mode of action, objective response
assessment results in relatively high SD rates and relatively
low PR and CR rates, as seen in our study, which could
lead to possible underestimation of drug efficacy [14, 15,
28–30]. FDG-PET/CT visualizes the anatomically attenua-
tion corrected glucose metabolism and thereby depicts
changes in tumor-cell metabolism [2, 31–33]. As targeted
therapies are considered to reduce metabolism rather than
size, it is suggested that metabolic imaging could be able
to depict effect more fulfilling than morphological imag-
ing and thereby perhaps provide more applicable RRs [10,
14, 34]. On the other hand, metabolism could be affected
by concomitant medication (i.e., prednisolone). Thus,
international consensus on methodology for FDG-PET/
CT-based response assessment has not yet been fully
implemented which complicates comparison of results
between trials. Yet, criteria sets for standardization of
methodology have been developed, initially by the EORTC
PET study group (1999) [35] and latest with PERCIST
(2009) by Wahl et al. [19, 36], applied in this study.
RECIST 1.0 and PERCIST response distribution corre-
lated, although differently, with survival. Other study
groups have found similar correlations between reduction
in FDG-uptake and survival of patients with CRC [9, 34,
37, 38]. The HR between the PR and SD group was 1.9
and insignificant but between the PMR and SMD group
the HR was 3.6 and significant. On the other hand, the
HR between the PR and PD group was 5.4 and significant
while it was 1.3 between the PMR and PMD group and
insignificant. In other words, the HR for OS for respond-
ers (PR/PMR) versus nonresponders (PD/PMD) was
higher for CT- than for FDG-PET/CT evaluation. Yet, the
study was not powered to draw firm conclusions about
survival outcome.
Four patients with SD shifted to PMD. These patients
would have had a shorter treatment span if continuation
had been based on metabolic tumor changes. However,
no patients with PR shifted to PMD, suggesting that
patients with a distinct treatment response on CT would
theoretically not be deprived treatment if morphologic
response assessment was to be replaced with metabolic in
future clinical trial settings.
With morphological imaging criteria, RRs of mCRC
patients harboring KRAS mutations treated with cetux-
imab have been found significantly lower than for
patients without KRAS mutations and there has since
2008/2009 been international consensus that these
patients should not be treated with cetuximab [17, 39,
40]. In our study, the above mentioned correlation
between the CT-based RR and KRAS status was retrieved.
This was, however, not the case with the FDG-PET/CT-
based evaluation as FDG-PET/CT identified a relatively
large number of KRAS mutation carrying patients who
had a metabolic but not a distinct morphologic treatment
response. Explanations for this finding could be that
FDG-PET/CT, being a more sensitive method than CT,
visualizes the tumor changes in the patients where the
treatment induces enough reduction in tumor activity to
hinder progression but not enough to reduce size.
Thereby presumably visualizing the metabolic changes in
the patients with SD according to CT evaluation. In the
clinic, we continue treatment in patients showing both
PR and SD and it would, therefore, be without clinical
consequences to replace CT evaluation with FDG-PET/CT
for the time being. However, we found that PD and PMD
were not coincident in all patients. So in a future trial,
where patients were to be randomized between evaluation
with either CT or FDG-PET/CT, individual treatment
course could to some degree differ depending on the
applied evaluation method and might thereby influence
treatment duration. Furthermore, it would be interesting
to see if and how treatment duration according to evalua-
tion method would influence survival, a question this
study is not designed to answer.
Matching a specific drug or regimen to the visualization
modality that as optimal as possible depict the expected
type of therapy-effect is important to not miss the full
potential or overestimate the effect of a drug or regimen
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and to optimize patient care [5, 16]. Imaging stratification
is an important part of treatment stratification and clinical
trial design where also parallel testing of standard and
alternative imaging is relevant to develop image stratifica-
tion toward being cancer type and therapy specific.
Conclusion
Morphological response assessment by CT, using RECIST
1.0, and metabolic response assessment by FDG-PET/CT,
using PERCIST, were incongruent and agreement poor. A
large part of the patients shifted from SD with CT evalua-
tion to PMR when evaluated with FDG-PET/CT. RECIST
1.0 and PERCIST response distribution tended to corre-
late, although differently, with survival. With RECIST 1.0,
no patients with PR but a larger fraction of patients with
SD had KRAS mutations while with PERCIST, a larger
fraction of the patients with PMR had KRAS mutations.
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